Business Wire

Forge Biologics Fuels Gene Therapy Manufacturing Engine with Launch of Plasmid DNA Manufacturing Services to Support AAV Clients

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the new availability of plasmid DNA manufacturing to its ...
Yahoo Finance

Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases

COLUMBUS, Ohio, May 14, 2025--(BUSINESS WIRE)--Forge Biologics ("Forge"), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced an AAV ...
Nasdaq

Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership

Partnership to Bolster Solid Biosciences’ Gene Therapy Pipeline, Including AAV Process Development, Scale Up and cGMP Manufacturing Services Forge will provide an adeno-associated viral (AAV) vector ...
KXAN

Affinia Therapeutics and Forge Biologics Announce AAV cGMP Manufacturing Partnership to Advance Affinia Therapeutics' Pipeline of Next-Generation Gene Therapies to the Clinic

WALTHAM, Mass. and COLUMBUS, Ohio, Nov. 13, 2024 /PRNewswire/ -- Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a pipeline of rationally designed adeno-associated virus (AAV ...
Business Wire

Myrtelle and Forge Biologics Announce Viral Vector and Plasmid DNA cGMP Manufacturing Partnership

WAKEFIELD, Mass. & COLUMBUS, Ohio--(BUSINESS WIRE)--Myrtelle Inc., (Myrtelle), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, and ...
GEN

Conquering the Complexities of AAV Manufacturing: Advances in Efficiency, Scalability, Compliance

Adeno-associated viruses (AAV) have emerged as pivotal delivery vehicles for gene therapy due to their overall safety (less immunogenic), efficiency (broad tropism), and long-term gene expression.
PharmiWeb

Ascidian Therapeutics and Forge Biologics Announce Manufacturing Partnership to Advance RNA Editing Therapy for Stargardt Disease

Forge’s FUEL™ platform and cGMP manufacturing services support the production of AAV for Ascidian’s ACDN-01, the most advanced genetic therapy targeting the underlying cause of Stargardt disease ...